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Abstract: Phenoxyacetohydrazide Schiff base analogs 1–28 have been synthesized and their 
in vitro β-glucouoronidase inhibition potential studied. Compounds 1 (IC50 = 9.20 ± 0.32 µM), 
5 (IC50 = 9.47 ± 0.16 µM), 7 (IC50 = 14.7 ± 0.19 µM), 8 (IC50 = 15.4 ± 1.56 µM),   
11 (IC50 = 19.6 ± 0.62 µM), 12 (IC50 = 30.7 ± 1.49 µM), 15 (IC50 = 12.0 ± 0.16 µM),  
21 (IC50 = 13.7 ± 0.40 µM) and 22 (IC50 = 22.0 ± 0.14 µM) showed promising   
β-glucuronidase inhibition activity, better than the standard (D-saccharic acid-1,4-lactone, 
IC50 = 48.4 ± 1.25 µM). 
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1. Introduction 
A range of bioactivities are reported for hydrazide-hydrazone compounds, such as antibacterial, 
anticonvulsant, antimalarial, analgesic, antiinflammatory, antiplatelets, antifungal, antituberculosis, 
and anticancer activities [1–6]. A variety of semicarbazones, thiosemicarbazones and guanyl hydrazones 
are found to be key compounds for drug design [7], for metal complexes [8], organocatalysis [9], and 
are used for the preparation of heterocyclic rings [10]. A few pyrazole carbohydrazide hydrazone 
derivatives [11] and novel 3-aryl-1-arylmethyl-1H-pyrazole-5-carbohydrazide hydrazones were found 
to be proliferation inhibitors of A549 cells [12,13] Some evidence proposes a pharmacophoric 
character for the hydrazone moiety present in phenylhydrazone derivatives in the inhibition of 
cyclooxygenase [14]. Antioxidant [15–18], antiglycation [19–22] and antileishmanial [23] activity 
have recently been reported, as well as applications in mass spectrometry [24]. 
The present work aimed to investigate the potential activity of a series of aryl hydrazide-hydrazones 
as in vitro β-glucouoronidase inhibitors. In our designed analogues substituted phenoxy-acetohydrazides 
were treated with different aromatic aldehydes to scrutinize their potential activity. The earlier reported 
literature [25] showed that β-glucouoronidase is a lysosomal enzyme, present in many organs like the 
spleen, kidney, lung, bile, serum and urine, etc., where its specific task is to catalyze the cleavage of 
glucuronosyl-O-bonds [26–28]. It degrades glucuronic acid-containing glycosaminoglycans, like 
heparan sulfate, chondroitin sulfate and dermatan sulfate [29]. An elevated level of β-glucouoronidase 
was observed in various types of malignancies, such as breast, lung and gastrointestinal tract 
carcinomas, and melanomas. Its high expression also observed in bronchial tumors [30]. On the other 
hand, mucopolysaccharidosis type VII (MPS VII; Sly Syndrome) is caused by the deficiency of human 
β-glucuronidase [31]. The circulating level of β-glucuronidase is also useful as a lysosomal enzyme in 
children affected by leprosy. In borderline tuberculoid patients and lepromatous patients higher activity 
of this enzyme was also observed. 
2. Results and Discussion 
2.1. Chemistry 
Lead identification is a well defined tool in drug design and discovery. Our research group has been 
involved for a decade in lead discovery programs in search of novel therapeutic agents. We have 
earlier reported Schiff bases of different classes of organic compounds in the search for lead molecules 
with different biological activities [32–34]. Earlier, our group reported the leishmanicidal and   
β-glucurinodase inhibition potential of hydrazides derived from the corresponding esters [35–38]. In 
view of the formerly reported work we synthesized hydrazide Schiff bases and screened their potential 
biological activities [39–42]. Acylhydrazide Schiff base derivatives 1–28 were synthesized from an 
acylhyrazide by condensing it with different aromatic aldehydes and acetophenones under reflux Molecules 2014, 19  8790 
 
 
conditions in ethanol for 2–3 h (Scheme 1). The crude products (Table 1) were further recrystallized 
from methanol and needle-like crystals were obtained in most of the cases. The starting acylhydrazide was 
synthesized from ester of ethyl 2-(4-chloro-2-methylphenoxy) acetate by refluxing with hydrazine hydrate. 
Scheme 1. Synthetic scheme for benzohydrazide followed by synthesis of Schiff bases 1–28. 
O
O
O
Me Cl
N
H
Me
NH2
O
O
Cl
N2H4 H2O
R1 R2CO
CH3CH2OH
NC
R1
R2
O
O
Me
Cl
reflux, 2 h
reflux, 3 h
NH
 
Table 1. Synthesis of acylhydrazide Schiff base derivatives 1–28. 
Compound 
No. 
R1 R 2 
Yield 
(%)
Compound 
No. 
R1 R 2 
Yield 
(%) 
1 
 
H 81  15 
 
H 88 
2 
 
H 85  16 
 
H 92 
3 
 
H 93  17 
 
CH3 94 
4 
 
H 87  18 
 
H 89 
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Table 1. Cont. 
Compound 
No.  R1 R 2  Yield 
(%)
Compound 
No.  R1 R 2  Yield 
(%) 
5 
 
H 83  19 
 
CH3 87 
6 
 
H 86  20 
 
H 84 
7 
 
H 89  21 
 
H 94 
8 
 
H 91  22 
 
H 93 
9 
 
H 94  23 
 
H 91 
10 
 
H 82  24 
 
CH3 95 
11 
 
H 88  25 
 
H 91 
12 
S
5' 2'
4'
 
H 91  26 
 
H 88 
13 
 
H 86  27 
 
H 81 
14 
 
H 93  28 
 
H 93 
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2.2. β-Glucuronidase 
Synthetic acyl hydrazides Schiff bases 1–28 were screened for their in vitro potential as   
β-glucoronidase inhibitors. The in vitro β-glucornidase inhibitory potential was evaluated by using the 
literature protocol [43]. Compounds 1–28 showed diversified β-glucoronidase inhibitory activities, 
with IC50 values ranging between 9.20–30.7 µM. Compounds 1, 5, 7, 8, 11, 12, 15, 21, and 22 showed 
excellent β-glucoronidase inhibitory activities, with IC50 values of 9.20 ± 0.32, 9.47 ± 0.16, 14.7 ± 0.19, 
15.4 ± 1.56, 19. ± 0.62, 30.7 ± 1.49, 12.0 ± 0.16, 13.7 ± 0.40, and 22.0 ± 0.14 µM, respectively, and 
the remaining compounds exhibited no activity (Table 2). 
Table 2. In vitro β-glucuronidase activity of compounds 1–28. 
Compounds IC50 (μM ± SEM 
a) Compounds  IC50 (μM ± SEM 
a) 
1  9.20 ± 0.32  15  12.0 ± 0.16 
2  NA 
b  16  NA 
b 
3  NA 
b  17  NA 
b 
4  NA 
b  18  NA 
b 
5  9.47 ± 0.16  19  NA 
b 
6  NA 
b  20  NA 
b 
7  14.7 ± 0.19  21  13.7 ± 0.40 
8  15.4 ± 1.56  22  22.0 ± 0.14 
9  NA 
b  23  NA 
b 
10  NA 
b  24  NA 
b 
11  19.6 ± 0.62  25  NA 
b 
12  30.7 ± 1.49  26  NA 
b 
13  NA 
b  27  NA 
b 
14  NA 
b  28  NA 
b 
D-saccharic acid-1,4-lactone 
c  48.4 ± 1.25  -  - 
SEM 
a is the standard error of the mean; NA 
b Not active; 
c standard inhibitor for β-glucuronidase. 
It was observed that both the substituents’ nature and their position at the benzilidine part have 
great importance in the β-glucoronidase inhibition activity of a compound, and apparently the acylium 
part does not take part in the activity (Figure 1). 
Figure 1. The two parts of molecule on which activity is based. 
 
The best activity was shown by compound 1 (IC50 = 9.20 ± 0.32 µM, fivefold better than the 
standard D-saccharic acid-1,4-lactone, IC50 value 48.4 ± 1.25 µM) which has a methoxy group at the 
ortho position. Surprisingly, a marked decline in activity (to the point of being inactive) was observed Molecules 2014, 19  8793 
 
 
in analog 2 which has a methoxy residue at the para position instead of the ortho position as in 
compound 1. This huge difference in the activities of compounds 1 and 2 clearly indicates that a 
specific group at a specific position of the benzylidine phenyl ring part plays a vital role in making a 
potent  β-glucornidase inhibitor in this type of compounds. The excellent activity of compound 5  
(IC50 = 9.47 ± 0.16 µM) having an ortho nitro group on the phenyl ring as compared to the inactivity 
of its closely related derivative 6 having a meta nitro group on phenyl ring proves our hypothesis that a 
suitable group at a suitable position of the phenyl ring of benzilidine part of molecules is a prerequisite 
for β-glucornidase inhibitory potential in these N-acylhydrazone Schiff bases. Comparison of activity 
of chloro-containing compounds 7 (IC50 = 14.7 ± 0.19 µM), 8 (IC50 = 15.4 ± 1.56 µM), and 9 
(inactive) demonstrated that the nature and location of a substitution is important for β-glucornidase 
inhibitory potential. Dichloro-substituted compounds 9 and 10 were found to be completely inactive 
which further proves our hypothesis. Compound 11 (IC50 = 19.6 ± 0.62 µM) having an ortho fluoro group 
showed excellent activity, but a little less than analogous chloro compounds 7 and 8. We also 
evaluated the effect of heterocyclic ring-containing derivatives, and it was observed that the five 
membered heterocyclic thiophene ring-containing derivative 12 (IC50 30.7 ± 1.49 µM) produced 
remarkable activity, while on the other hand five membered heterocyclic rings like furan and its methyl 
derivatives  13 and 14 were found to be completely inactive. Almost all mono-, di- and trihydroxy 
substituted compounds 16,  17,  18,  19, and 20 found to be completely inactive, but unexpectedly 
compound 15 (IC50 = 12.0 ± 0.16 µM) which bears 2,3-dihydroxy substitution, was found to be very 
efficient and displayed remarkable activity, better than the standard, but, compound 16, also a   
3,4-dihydroxy derivative did not show any activity. N-acylhydrazones Schiff base 21 (IC50 = 13.7 ± 
0.40 µM) synthesized from 1-napthaldehyde was found to be more active than 22 (IC50 = 22.0 ± 0.14 µM) 
which was synthesized from 2-napthaldehyde, both without any substitution. Remaining compounds 
23–28 were found to be completely inactive. This pattern of activity reveals that the substituent and its 
position on the phenyl ring of benzylidine part is a driving force for β-glucornidase inhibition activity. 
In conclusion, a number of potential lead molecules has been identified as β-glucuronidase 
inhibitors. Compounds 1, 5, 7, 8, 11, 12, 15, 21, and 22 demonstrated excellent activity and it is 
anticipated that by slight synthetic modification in these molecules, some new most active   
β-glucuronidase inhibitors can be developed. 
3. Experimental  
3.1. General Information 
1H-NMR experiments were performed on an Avance-Bruker AM 300 MHz instrument   
(Wissembourg Cedex, France). A Carlo Erba Strumentazione-Mod-1106 (Milan, Italy) used to 
measure CHN analysis. EI MS was performed on a Finnigan MAT-311A (Bremen, Germany). Thin 
layer chromatography (TLC) was carried out on pre-coated silica gel glass plates (Kieselgel 60, 254,  
E. Merck, Darmstadt, Germany). The chromatograms were visualized by UV at 254 and 365 nm or 
iodine vapours. 
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3.2. Biological Assays 
β-Glucuronidase (E.C. 3.2.1.31 from bovine liver, G-0251) and p-nitrophenyl-β-D-glucuronide  
(N-1627) were purchased From Sigma Chemical Co. (St. Louis, MO, USA). Anhydrous Na2CO3 and 
all other reagents of standard grade were obtained from E. Merck. The anhydrous EtOH and CHCl3 
used in the experiments were dried employing the standard methods. All other solvents and reagents 
like the benzoyl chloride were of standard grade. 
3.3. Assay for β-D-Glucuronidase 
β-D-Glucuronidase inhibition was determined by measuring the absorbance of the p-nitrophenol 
which is produce from the substrate at 405 nm. The total reaction volume was 250 µL. The reaction 
mixture contains 5 µL of test compound solution, 185 µL of 0.1 M acetate buffer, and 10 µL of 
enzyme, and it was incubated at 37 °C for 30 min. The plates were read on a multiplate reader at  
405 nm after the addition of 50 µL of 0.4 mM p-nitrophenyl-β-D-glucuronide. All assays were 
performed in triplicate. 
3.4. Typical Method for the Synthesis of Compounds 1–28 
To a mixture of 2-(4-chloro-2-methylphenoxyacetic acid) hydrazide (1 mmol) in methanol (25 mL) 
was added a substituted aldehyde (1 mmol) and 3 drops of glacial acetic acid and the mixture was 
refluxed for 3 h. After completion of the reaction (TLC analysis), it was cooled and evaporated on a 
rotary evaporator. The resultant crude product was crystallized from methanol to afford 80%–90% 
yields of pure product. The structures of synthetic compounds 1–28 were determined by different 
spectroscopic techniques, including 
1H-NMR, and EI MS spectroscopy. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3-(2-methoxyphenyl)-2-propenylidene]acetohydrazide ( 1). Yield: 
68%; 
1H-NMR (DMSO-d6)  δ: 8.04 (d, 1H, J  = 9.3 Hz, N=CH-CH), 7.63 (dd, 1H, J5',6'  = 7.8 Hz,  
J5',3' = 1.2 Hz, H-6'), 7.34 (dd, 1H, JCH-HC=CH = 8.1 Hz, CH-HC=CH), 7.23 (d, 1H, JHC=CH = 6 Hz, 
HC=CH), 7.12–7.20 (m, 2H, H-3/5) 6.85–7.06 (m, 3H, H- 3'/4'/5'), 6.80 (d, 1H, J6,5 = 9 Hz, H-6), 5.17 (s, 
2H, -OCH2), 3.84 (s, 3H, -OCH3), 2.23 (s, 3H, CH3); EI MS: m/z (%) 358 (M
+, 30), 327 (100),189 
(40), 175 (55), 159 (100), 125 (75.0), Anal. Calcd for C19H19ClN2O3, C = 63.60, H = 5.34, N = 7.81. 
Found: C = 63.55, H = 5.31, N = 7.80. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3-(4-methoxyphenyl)-2-propenylidene]acetohydrazide ( 2). Yield: 
70%; 
1H-NMR (DMSO-d6) δ: 8.02 (d, 1H, J = 9.3Hz, N=CH-CH), 7.55 (d, 2H, J2',3' = J6',5' = 8.7 Hz,  
H-2'/6'),7.12–7.23 (m, 2H, H-3/5),7.01 (d, 2H, J3',2' = J5',6' = 7.0 Hz, H-3'/5'), 6.76–6.87 (m, 2H, HC = CH), 
6.92 (d, 1H, J5,6  = 8.4 Hz, H-6), 5.03 (s, 2H, -OCH2), 3.76 (s, 3H, OCH3), 2.21 (s, 3H, CH3); m/z (%) 
358 (M
+, 95), 189 (40), 175 (85), 159 (100), 125 (60). Anal. Calcd for C19H19ClN2O3, C = 63.60,  
H = 5.34, N = 7.81. Found: C = 63.57, H = 5.32, N = 7.79. 
2-(4-Chloro-2-methylphenoxy)-N'-[(4-ethoxyphenyl)methylidene]acetohydrazide (3). Yield: 80%; 
1H-NMR 
(DMSO-d6) δ: 8.20 (s, 1H, -N=CH), 7.62 (d, 2H, J2',3' = J6',5' = 8.7 Hz, H-2'/6'), 7.23–7.12 (m, 2H, H-3/5), 
6.84 (d, 2H, J3',2' = J5',6' = 8.7 Hz, H-3'/5'), 6.84 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.13 (s, 2H, OCH2), 4.04 (q, Molecules 2014, 19  8795 
 
 
2H, J = 6.9 Hz, -CH2), 2.22 (s, 3H, -CH3), 1.32 (t, 3H, J = 6.9 Hz, -CH3); EI MS: m/z (%) 347 (M
+, 56), 
205 (95), 155 (89), 147 (92), 119 (73). Anal. Calcd for C18H19ClN2O3, C = 62.34, H = 5.52, N = 8.08. 
Found: C = 62.33, H = 5.50, N = 8.03. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3,4,5-trimethoxyphenyl) methylidene]acetohydrazide ( 4). Yield: 
72%; 
1H-NMR (DMSO-d6) δ: 8.43 (s, 1H, -N=CH), 7.56 (d, 1H, J2',6' = 2.7 Hz, H-2'), 7.23 (m, 1H, H-5), 
7.13 (d, 1H, J3,5 = 2.7 Hz, H-3), 6.92(s, 1H, H-6'), 6.83 (d, 1H, J5,6 = 8.7 Hz H-6), 5.13 (s, 2H, -OCH2), 
3.82 (s, 9H, -OCH3), 2.22 (s, 3H, -CH3); EI MS: m/z (%) 392 (M
+, 62.1), 251 (15.5), 193 (100), 179 
(88.9), 155 (26.8). Anal. Calcd for C19H21ClN2O5, C = 58.09, H = 5.39, N = 7.13. Found: C = 58.05,  
H = 5.37, N = 7.11. 
2-(4-Chloro-2-methylphenoxy)-N'-[(2-nitrophenyl)methylidene]acetohydrazide (5). Yield: 65%; 
1H-NMR 
(DMSO-d6) δ: 8.09(s, 1H, N=CH), 8.29 (m, 2H, H-4'/5'), 7.98 (d, 2H, J3',4' = J6',5' = 9, H-3'/6') 7.24 (m, 
1H, H-5), 7.13 (d, 1H, J3,5 = 2.7 Hz, H-3), 6.89 (d, 1H, J6,5 = 8.7, H-6), 5.22 (s, 2H, -OCH2), 2.22 (s, 3H, 
-CH3); EI MS: m/z (%) 347 (M
+, 72), 206 (100), 155 (83.3), 125 (75.8). Anal. Calcd for C16H14ClN3O4, 
C = 55.26, H = 4.06, N = 12.08. Found: C = 55.23, H = 4.02, N = 12.04. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3-nitrophenyl)methylidene]acetohydrazide (6). Yield: 70%; 
1H-NMR 
(DMSO-d6) δ: 8.40 (s, 1H, -N=CH), 8.51 (d,1H, J5',6' = 7.2 Hz H-6'), 8.12–8.25 (m, 2H, H-2'/5'), 7.76 (m, 
1H, H-4'), 7.12-7.24 (m, 2H, H-3/5), 6.90 (dd, 1H, J6,5 = 6.2 Hz, H-6), 5.22 (s, 2H, OCH2), 2.23 (s, 3H, 
CH3); EI MS: m/z (%) 347 (M
+, 92), 206 (100), 178 (28.4), 141 (17.5), 125 (39.9). Anal. Calcd for 
C19H21ClN2O5, C = 58.09, H = 5.39, N = 7.13. Found: C = 58.06, H = 5.37, N = 7.12. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(4-chlorophenyl)methylidene]acetohydrazide (7). Yield: 63%; 
1H-NMR 
(DMSO-d6)  δ: 8.27 (s, 1H, -N=CH), 7.73 (d, 2H, J2',3' = J6',5' = 8.7 Hz, H-2'/6'), 7.51 (d, 2H,   
J3',2' = J5',6' = 8.1 Hz, H-3'/5'), 7.13–7.23 (m, 2H, H-3/5), 6.89 (d, J6,5 = 7.8 Hz, 1H, H-6), 5.15 (s, 2H,  
-OCH2), 2.19 (s, 3H, CH3); EI MS: m/z (%) 336 (M
+, 20), 195 (35), 155 (55), 125 (80), 89 (100). Anal. 
Calcd for C16H14Cl2N2O2, C = 56.99, H = 4.18, N = 8.31. Found: C = 56.95, H = 4.15, N = 8.28. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(2-chlorophenyl)methylidene]acetohydrazide (8). Yield: 66%; 
1H-NMR 
(DMSO-d6) δ: 8.26 (s,1H, -N=CH), 7.77 (m, 2H, H-3'/6'), 7.48 (br.t, 2H, J4',5' = J5',4' = 8.5 Hz, H-4'/5'), 
7.13–7.24 (m, 1H, H-3/5), 6.89 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.15 (s, 2H, -OCH2), 2.23 (s, 3H, -CH3), 
2.19 (s, 3H, CH3); EI MS: m/z (%) 336 (M
+, 10), 195 (30), 155 (40), 125 (75), 89 (100). Anal. Calcd for 
C16H14Cl2N2O2, C = 56.99, H = 4.18, N = 8.31. Found: C = 56.96, H = 4.15, N = 8.27. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3,4-dichlorophenyl)methylidene]acetohydrazide ( 9). Yield: 70%; 
1H-NMR (DMSO-d6) δ: 8.25 (s, 1H, =N-CH), 7.96 (s, 1H, H-2'), 7.68 (br. s, 2H, 5'/6'), 7.12–7.23 (m, 
2H, H-3/5), 6.88 (d, 1H, J6,5 = 7.0 Hz H-6), 5.08 (s, 2H, OCH2), 2.22 (s, 3H, CH3); EI MS: m/z (%) 
371 (M
+, 92.2), 228 (100), 155 (87.1), 125 (89.8). Anal. Calcd for C16H13Cl3N2O2, C = 51.71, H = 3.53, 
N = 7.54. Found: C = 51.68, H = 3.50, N = 7.52. 
2-(4-Chloro-2-methylphenoxy)-N'-[(2, 6-dichlorophenyl)methylidene]acetohydrazide (10). Yield: 60%; 
1H-NMR (DMSO-d6) δ: 8.48 (s,1H, -N=CH), 7.57 (d, 2H, J3',4' = J5',4' = 8.7 Hz, H-3'/5'), 7.44 (dd, 1H, 
J4,5 = 7.2 Hz, H-4'), 7.24–7.11 (m, 2H, H-3/5), 6.78 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.09 (s, 2H, -OCH2), 2.18 Molecules 2014, 19  8796 
 
 
(s, 3H, CH3); EI MS: m/z (%) 370 (M
+, 17.3), 229 (39.5), 155 (60.1), 125 (100), 89 (62). Anal. Calcd for 
C16H13Cl3N2O2, C = 51.71, H = 3.53, N = 7.54. Found: C = 51.66, H = 3.51, N = 7.52. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(2-fluorophenyl)methylidene]acetohydrazide ( 11). Yield: 74%; 
1H-NMR (DMSO-d6) δ: 8.52 (s, 1H, -N=CH), 7.95 (dd, 1H, J4',5' = 8.1 H-5') 7.48 (dd, 1H, J6',5' = 6.9 Hz, 
H-6'), 7.25-7.31 (m, 2H, H-3'/4'), 7.12–7.21 (m, 2H, H-3/5), 6.90 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.17 (s, 
2H, -OCH2), 2.23 (s, 3H, CH3); EI MS: m/z (%) 320 (M
+, 12), 179 (80), 125 (100), 89 (75.8). Anal. Calcd 
for C16H14ClFN2O2, C = 59.91, H = 4.40, N = 8.73. Found: C = 59.89, H = 4.39, N = 8.72. 
2-(4-Chloro-2-methylphenoxy)-N'-[3-thienylmethylidene]acetohydrazide ( 12). Yield: 68%; 
1H-NMR 
(DMSO-d6) δ: 8.07 (s, 1H, -N=CH), 7.12–7.24 (m, 3H, H-3, 5, 6), 6.73–9.92 (m, 3H, H-2'/4'/5'), 5.10 
(s, 2H, -OCH2), 2.22 (s, 3H, CH3); EI MS: m/z (%) 308 (M
+, 15), 199 (10), 155 (45), 125 (100). Anal. 
Calcd for C14H13ClN2O2S, C = 54.46, H = 4.24, N = 9.07. Found: C = 54.45, H = 4.22, N = 9.04. 
2-(4-Chloro-2-methylphenoxy)-N'-[-2-furylmethylidene]acetohydrazide ( 13). Yield: 70%; 
1H-NMR 
(DMSO-d6) δ: 8.17 (s, 1H, -N=CH), 7.11–7.23 (m, 2H, H-3,5), 6.90 (d, 2H, J3',4'= J5',4' = 3.3 Hz, H-3'/5'), 
6.81(d, 1H, J6,5 = 8.7 Hz, 6), 6.62 (dd, 1H, J4,3 = J4,5 = 3.3 Hz, 4'), 5.07 (s, 2H, -OCH2), 2.22 (s, 3H,  
-CH3); EI MS: m/z (%) 292 (M+, 35), 155 (50), 151 (80.), 125 (100). Anal. Calcd for C14H13ClN2O3, 
C = 57.44, H = 4.48, N = 9.57. Found: C = 57.44, H = 4.46, N = 9.56. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(5-methyl-2-furyl)methylidene]acetohydrazide ( 14). Yield: 72%; 
1H-NMR (DMSO-d6) δ: 8.07 (s, 1H, -N=CH), 7.11–7.23 (m, 2H, H-3,5), 6.88 (d, 1H, J5,6 = 8.7 Hz, H-6), 
6.80 (d, 1H, J3',4' = 5.4 Hz, 3'), 6.24 (d, 1H, J4',3' = 2.7 Hz, 4'), 5.07 (s, 2H, -OCH2), 2.21 (s, 3H, -CH3) 
2.19 (s, 3H, -CH3); EI MS: m/z (%) 306 (M
+, 20), 65 (30), 137 (100), 125 (40). Anal. Calcd for 
C15H15ClN2O3, C = 58.73, H = 4.93, N = 9.13. Found: C = 58.70, H = 4.96, N = 9.10. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(2,3-dihydroxyphenyl)methylidene]acetohydrazide ( 15). Yield: 76%; 
1H-NMR (DMSO-d6) δ: 8.41 (s,1H, -N=CH), 7.24 (m, 1H, H-5), 7.13 (d, 1H, J3,5 = 2.7 Hz, H-3), 6.89 
(d, 1H, J5',6' = 8.7 Hz, H-6'), 6.83 (d, 1H, J6,5 = 8.7 Hz, H-6), 6.71 (m, 2H, H-3'/4'), 5.15 (s, 2H,  
-OCH2), 2.19 (s, 3H, -CH3); EI MS: m/z (%) 334 (M
+, 100),300 (9), 175 (89.7), 193 (35), 179 (50), 
137 (65), 125 (60). Anal. Calcd for C16H15ClN2O4, C = 57.41, H = 4.5, N = 8.37. Found: C = 57.40,  
H = 3.50, N = 8.36. 
2-(4-Chloro-2-methylphenoxy)-N'-[-(3,4-dihydroxyphenyl)methylidene]acetohydrazide ( 16). Yield: 68%; 
1H-NMR (DMSO-d6) δ: 8.06 (s, 1H, -N=CH), 7.12-7.19 (m, 2H, H-3/5),7.24 (d, 1H, J2',6' = 2.7 Hz, H-2'), 
6.85–6.92 (m, 2H ,H-5'/6'), 6.76 (d, J6,5 = 8.1 Hz, 1H, H-6), 5.10 (s, 2H, -OCH2), 2.22 (s, 3H, CH3); EI 
MS:  m/z  (%) 334 (M, 36.8), 193 (23.9), 155 (71.6), 125 (88.8), 77 (100). Anal. Calcd for 
C16H15ClN2O4, C = 57.41, H = 4.5, N = 8.37. Found: C = 57.39, H = 3.50, N = 8.37. 
2-(4-Chloro-2-methylphenoxy)-N'-[1-(4-hydroxyphenyl)ethylidene]acetohydrazide ( 17). Yield: 70%; 
1H-NMR (DMSO-d6) δ: 7.65 (d, 2H, J2',3' = J6',5' = 8.7 Hz , H-2'/6'), 7.23 (m, 1H, Hz H-6), 7.12 (d, 1H, 
J = 2.4 Hz, H-3), 6.90 (d, J3',2'= J5',6' = 8.7 Hz, 2H, H-3'/5'), 6.77 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.16 (s, 
2H, -OCH2), 2.19 (s, 6H, CH3); EI MS: m/z (%) 332 (M
+, 56.7), 191 (100), 177 (24.5), 149 (34.5), 134 Molecules 2014, 19  8797 
 
 
(37.9). Anal. Calcd for C17H16ClN2O3, C = 61.36, H = 5.15, N = 8.42. Found: C = 61.34, H = 5.14,  
N = 8.40. 
2-(4-Chloro-2-methylphenoxy)-N'-[(3-hydroxyphenyl)methylidene]acetohydrazide ( 18). Yield: 61%; 
1H-NMR (DMSO-d6) δ: 8.18 (s, 1H, -N=CH), 7.04-7.24 (m, 5H, Ar-H), 6.79–6.89 (m, 2H, H-5-6), 
5.14 (s, 2H, -OCH2), 2.22 (s, 3H,-CH3); EI MS: m/z (%) 318 (M
+, 97.6), 177 (100), 155 (71), 125 
(65.3). Anal. Calcd for C16H15ClN2O3, C = 60.29, H = 4.74, N = 8.79. Found: C = 69.27, H = 3.49,  
N = 8.34. 
2-(4-Chloro-2-methylphenoxy)-N'-[1-(2,4,6-trihydroxyphenyl)ethylidene]acetohydrazide (19). Yield: 62%; 
1H-NMR (DMSO-d6) δ: 8.16 (s, 1H, -N=CH), 7.21 (br.s, 2H, H-3'/5'), 7.16–7.23 (m, 2H, H-3/5), 6.86 (d, 
J6,5 = 8.7 Hz, 1H, H-6), 4.98 (s, 2H, -OCH2), 2.18 (s, 3H, CH3), 1.93 (s, 3H, CH3); EI MS: m/z (%) 254 
(M
+, 100), 155 (91.2), 142 (75.5), 125 (100), 113 (100), 99 (86.6). 
2-(4-Chloro-2-methylphenoxy)-N'-[(4-hydroxyphenyl)methylidene]acetohydrazide ( 20). Yield: 72%; 
1H-NMR (DMSO-d6) δ: 7.88 (s, 1H, -N=CH), 7.52 (d, 2H, d, 2H, J2',3' = J6',5' = 8.7 Hz , H-2'/6'), 7.24 (d, 
1H, J5,6 = 8.1 Hz, H-5), 7.13(d, 1H, J = 2.4 Hz, H-3), 6.88 (d, 2H, J3',2' = J5',6' = 8.7 Hz, H-3'/5'), 6.79 
(d, 1H, J6,5 = 8.7 Hz, H-6), 5.11 (s, 2H, -OCH2), 2.22 (s, 3H, CH3); EI MS: m/z (%) 318 (M
+, 9.30), 
199 (10.78), 177 (27.43), 155 (44), 125 (67.50), 77 (100). Anal. Calcd for C16H15ClN2O3, C = 60.29,  
H = 4.74, N = 8.79. Found: C = 69.26, H = 3.50, N = 8.34. 
2-(4-Chloro-2-methylphenoxy)-N'-[-1-naphthylmethylidene]acetohydrazide ( 21). Yield: 68%; 
1H-NMR 
(DMSO-d6) δ: 8.66 (s, 1H, N=CH), 8.83 (d, J = 8.1 Hz 1H, H-8'), 8.61 (d, 1H, J4',3' = 8.4 Hz, H-4'), 
8.02 (br, d, 2H, J = 7.8 Hz, H-2'/5'), 7.93 (d, 1H, J3',4' = 7.8 Hz, H-3') 7.65 (m, 2H, H-6'/7'), 7.14–7.25 
(m, 2H, H-3/5), 6.95 (d, J6,5 = 8.4 Hz, 1H, H-6), 5.24 (s, 2H, -OCH2), 2.26 (s, 3H, -CH3); EI MS: m/z 
(%) 352 (M
+, 100), 211(65), 199. Anal. Calcd for C20H17ClN2O2, C = 68.09, H = 4.86, N = 7.94. 
Found: C = 68.06, H = 4.84, N = 7.92. 
2-(4-Chloro-2-methylphenoxy)-N'-[-2-naphthylmethylidene]acetohydrazide ( 22). Yield: 70%; 
1H-NMR 
(DMSO-d6) δ: 8.43 (s, 1H, N=CH), 8.16 (t, 2H, J = 8.4 Hz, H-3',6'), 7.94 (br, s, 2H, H-5/4') 7.56 (t, 
2H, J5',6' = J8',7' = 9.6 Hz, H-5'/8'), 7.22 (s, 1H, H-1'), 7.17 (d, 1H, J7',8' = 8.7 Hz, H-7'), 6.92 (m, 2H,  
H-5/6), 5.23 (s, 2H, OCH2), 2.23 (s, 3H, CH3); EI MS: m/z (%) 352 (M
+, 72), 211 (60) 199 (35), 169 
(45), 153 (100), 127 (60). Anal. Calcd for C20H17ClN2O2, C = 68.09, H = 4.86, N = 7.94. Found:  
C = 68.04, H = 4.85, N = 7.91. 
2-(4-Chloro-2-methylphenoxy)-N'-[(5-Chloro-2-hydroxyphenyl)methylidene]acetohydrazide  (23). Yield: 
66; 
1H-NMR (DMSO-d6) δ: 8.23 (s,1H, -N=CH), 7.70 (d, 1H, J6',4'= 2.7 Hz H-6'),7.12–7.23 (m, 2H,  
H-3/5), 7.31 (m, 1H, H-4'), 6.93 (d, 1H, J3',4' = 7.8Hz, H-3'),6.86 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.17 (s, 
2H, -OCH2), 2.22 (s, 3H, -CH3); EI MS: m/z (%) 352 (M
+, 83.8), 210 (7.4), 197 (62.6), 155 (100), 141 
(46.8). Anal. Calcd for C16H14Cl2N2O3, C = 54.41, H = 4.00, N = 7.93. Found: C = 54.39, H = 4.00,  
N = 7.92. 
2-(4-Chloro-2-methylphenoxy)-N'-[1(2,4-dihydroxy-5-nitrophenyl)ethylidene]acetohydrazide ( 24). Yield: 
70%; 
1H-NMR (DMSO-d6) δ: 8.23 (s, 1H, H-6'), 7.17–7.23 (m, 2H, H-3/5), 6.89 (d, 1H, J6,5 = 8.7 Hz,  Molecules 2014, 19  8798 
 
 
H-6), 6.51 (s, 1H, H-3'), 4.82 (s, 2H, -OCH2), 2.26 (s, 3H, CH3), 2.21 (s, 3H, CH3); EI MS: m/z (%) 
392 (M
+, 64.4), 251 (72.1), 237 (100), 125 (89.9), 77 (68.5). Anal. Calcd for C16H14ClN3O6, C = 50.60, 
H = 3.72, N = 11.07. Found: C = 50.57, H = 3.70, N = 11.05. 
2-(4-Chloro-2-methylphenoxy)-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]acetohydrazide ( 25). Yield: 
59%; 
1H-NMR (DMSO-d6)  δ: 8.11 (s, 1H, -N=CH), 7.12–7.23 (m, 2H, H-3/5), 7.03 (s, 1H, H-2'),   
6.86–6.96 (m, 2H, H-5'/6') 6.83 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.12 (s, 2H, -OCH2), 3.78 (s, 3H, OCH3), 
2.23 (s, 3H, CH3); EI MS: m/z (%) 348 (M
+, 88.5), 207 (51), 193 (100), 155 (43), 125 (46.9). Anal. 
Calcd for C17H17ClN2O4, C = 58.54, H = 4.91, N = 8.03. Found: C = 58.53, H = 4.90, N = 8.02. 
2-(4-Chloro-2-methylphenoxy)-N'-{-[4-(methylsulfanyl)phenyl]methylidene}acetohydrazide ( 26). Yield: 
63%; 
1H-NMR (DMSO-d6) δ: 8.22 (s, 1H, -N=CH), 7.63 (d, 2H, J2,3 = J6,5 = 8.4 Hz, H-2'/6'), 7.31 (d, 2H, 
J3,2 =J5,6 = 8.4 Hz, H-3'/5'),7.23 (m, 1H, H-5), 7.13 (d, 1H, J = 2.7 Hz, H-3), 6.89 (d, J6,5 = 8.4Hz, 1H, 
H-6), 5.15 (s, 2H, -OCH2), 2.19 (s, 3H, CH3); EI MS: m/z (%) 348 (M
+, 60), 207 (25), 149 (100), 125 
(35), 118 (35). Anal. Calcd for C17H17ClN2O2S, C = 58.53, H = 4.91, N = 8.03. Found: C = 58.51,  
H = 4.90, N = 8.02. 
2-(4-Chloro-2-methylphenoxy)-N'-[(2-methylphenyl)methylidene]acetohydrazide ( 27). Yield: 67%;   
1H-NMR (DMSO-d6) δ: 8.25 (s, 1H, -N=CH), 7.78 (d, J = 7.5 Hz, 1H, H-6'), 7.30–7.21 (m, 3H,  
H-3'/4'/5'), 7.13-7.17 (m, 2H, H-3/5), 6.84 (d, 1H, J6,5 = 8.7 Hz, H-6), 5.15 (s, 2H, -OCH2), 2.23 (s,3H, 
-CH3), 2.19 (s, 3H, CH3); EI MS: m/z (%) 316 (M
+, 79.4), 199 (78.9), 175 (89.7), 155 (100), 141 
(93.2), 118 (94.2). Anal. Calcd for C17H17ClN2O2, C = 64.46, H = 4.41, N = 8.84. Found: C = 64.45,  
H = 4.40, N = 8.83. 
2-(4-Chloro-2-methylphenoxy)-N'-[(4-methylphenyl)methylidene]acetohydrazide ( 28). Yield: 63%;   
1H-NMR (DMSO-d6) δ: 8.23 (s, 1H, -N=CH), 7.59 (d, 2H, J2',3'= J6',5' = 7.8 Hz, H-2'/6'), 7.24 (d, 2H, 
J3',2'= J5',6' = 8.1 Hz, H-3'/5'),7.13 (d, J = 2.7 Hz, 1H, H-3), 7.17 (m, 1H, H-5), 6.85 (d, J6,5 = 8.7 Hz, 
1H, H-6), 5.15 (s, 2H, -OCH2), 2.32 (s, 3H, CH3), 2.19 (s, 3H, CH3); EI MS: m/z (%) 316 (M
+, 9.61), 
199 (10.80), 175 (36.26), 155 (47.70), 125 (71.62). Anal. Calcd for C17H17ClN2O2, C = 64.46,   
H = 4.41, N = 8.84. Found: C = 64.44, H = 4.40, N = 8.82. 
4. Conclusions  
A number of potential lead molecules 1, 5, 7, 8, 11, 12, 15, 21, and 22 have been identified as  
β-glucuronidase inhibitors and it is anticipated that by slight synthetic modification in these molecules, 
some new most active β-glucuronidase inhibitors can be developed. 
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